12:00 AM
Oct 28, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Alnylam preclinical data

In a mouse model of acute intermittent porphyria, ALN-AS1 rapidly and dose-dependently reduced aminolevulinate synthase-1 (ALAS-1) mRNA and...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >